Report cover image

Global Nonalcoholic Steatohepatitis Treatment Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 198 Pages
SKU # APRC20360377

Description

Summary

According to APO Research, the global Nonalcoholic Steatohepatitis Treatment market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Nonalcoholic Steatohepatitis Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.

The Asia-Pacific market for Nonalcoholic Steatohepatitis Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Nonalcoholic Steatohepatitis Treatment market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.

The Europe market for Nonalcoholic Steatohepatitis Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Nonalcoholic Steatohepatitis Treatment market include Arena Pharmaceuticals, Arisaph Pharmaceuticals, Cempra Pharmaceuticals, Galectin Therapeutics, Galmed Pharmaceuticals, Genfit, Gilead, Novo Nordisk and Vivus, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.

This report presents an overview of global market for Nonalcoholic Steatohepatitis Treatment, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Nonalcoholic Steatohepatitis Treatment, also provides the value of main regions and countries. Of the upcoming market potential for Nonalcoholic Steatohepatitis Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Nonalcoholic Steatohepatitis Treatment revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Nonalcoholic Steatohepatitis Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Nonalcoholic Steatohepatitis Treatment company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Nonalcoholic Steatohepatitis Treatment Segment by Company

Arena Pharmaceuticals
Arisaph Pharmaceuticals
Cempra Pharmaceuticals
Galectin Therapeutics
Galmed Pharmaceuticals
Genfit
Gilead
Novo Nordisk
Vivus
AstraZeneca
GSK
Roche
Nonalcoholic Steatohepatitis Treatment Segment by Type

Solid
Liquid
Nonalcoholic Steatohepatitis Treatment Segment by Application

Drug Store
Hospital
Hospital Pharmacy
Mail Order Pharmacy
Diagnostic Center
Specialized Clinic
Nonalcoholic Steatohepatitis Treatment Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Nonalcoholic Steatohepatitis Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Nonalcoholic Steatohepatitis Treatment key companies, revenue, market share, and recent developments.
3. To split the Nonalcoholic Steatohepatitis Treatment breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Nonalcoholic Steatohepatitis Treatment market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Nonalcoholic Steatohepatitis Treatment significant trends, drivers, influence factors in global and regions.
6. To analyze Nonalcoholic Steatohepatitis Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nonalcoholic Steatohepatitis Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nonalcoholic Steatohepatitis Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nonalcoholic Steatohepatitis Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nonalcoholic Steatohepatitis Treatment industry.
Chapter 3: Detailed analysis of Nonalcoholic Steatohepatitis Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Nonalcoholic Steatohepatitis Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Nonalcoholic Steatohepatitis Treatment in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.

Table of Contents

198 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Nonalcoholic Steatohepatitis Treatment Market Size, 2020 VS 2024 VS 2031
1.3 Global Nonalcoholic Steatohepatitis Treatment Market Size (2020-2031)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Nonalcoholic Steatohepatitis Treatment Market Dynamics
2.1 Nonalcoholic Steatohepatitis Treatment Industry Trends
2.2 Nonalcoholic Steatohepatitis Treatment Industry Drivers
2.3 Nonalcoholic Steatohepatitis Treatment Industry Opportunities and Challenges
2.4 Nonalcoholic Steatohepatitis Treatment Industry Restraints
3 Nonalcoholic Steatohepatitis Treatment Market by Company
3.1 Global Nonalcoholic Steatohepatitis Treatment Company Revenue Ranking in 2024
3.2 Global Nonalcoholic Steatohepatitis Treatment Revenue by Company (2020-2025)
3.3 Global Nonalcoholic Steatohepatitis Treatment Company Ranking (2023-2025)
3.4 Global Nonalcoholic Steatohepatitis Treatment Company Manufacturing Base and Headquarters
3.5 Global Nonalcoholic Steatohepatitis Treatment Company Product Type and Application
3.6 Global Nonalcoholic Steatohepatitis Treatment Company Establishment Date
3.7 Market Competitive Analysis
3.7.1 Global Nonalcoholic Steatohepatitis Treatment Market Concentration Ratio (CR5 and HHI)
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.7.3 2024 Nonalcoholic Steatohepatitis Treatment Tier 1, Tier 2, and Tier 3 Companies
3.8 Mergers and Acquisitions Expansion
4 Nonalcoholic Steatohepatitis Treatment Market by Type
4.1 Nonalcoholic Steatohepatitis Treatment Type Introduction
4.1.1 Solid
4.1.2 Liquid
4.2 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Type
4.2.1 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Type (2020 VS 2024 VS 2031)
4.2.2 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Type (2020-2031)
4.2.3 Global Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type (2020-2031)
5 Nonalcoholic Steatohepatitis Treatment Market by Application
5.1 Nonalcoholic Steatohepatitis Treatment Application Introduction
5.1.1 Drug Store
5.1.2 Hospital
5.1.3 Hospital Pharmacy
5.1.4 Mail Order Pharmacy
5.1.5 Diagnostic Center
5.1.6 Specialized Clinic
5.2 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Application
5.2.1 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Application (2020 VS 2024 VS 2031)
5.2.2 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Application (2020-2031)
5.2.3 Global Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application (2020-2031)
6 Nonalcoholic Steatohepatitis Treatment Regional Value Analysis
6.1 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Region: 2020 VS 2024 VS 2031
6.2 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Region (2020-2031)
6.2.1 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Region: 2020-2025
6.2.2 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Region (2026-2031)
6.3 North America
6.3.1 North America Nonalcoholic Steatohepatitis Treatment Sales Value (2020-2031)
6.3.2 North America Nonalcoholic Steatohepatitis Treatment Sales Value Share by Country, 2024 VS 2031
6.4 Europe
6.4.1 Europe Nonalcoholic Steatohepatitis Treatment Sales Value (2020-2031)
6.4.2 Europe Nonalcoholic Steatohepatitis Treatment Sales Value Share by Country, 2024 VS 2031
6.5 Asia-Pacific
6.5.1 Asia-Pacific Nonalcoholic Steatohepatitis Treatment Sales Value (2020-2031)
6.5.2 Asia-Pacific Nonalcoholic Steatohepatitis Treatment Sales Value Share by Country, 2024 VS 2031
6.6 South America
6.6.1 South America Nonalcoholic Steatohepatitis Treatment Sales Value (2020-2031)
6.6.2 South America Nonalcoholic Steatohepatitis Treatment Sales Value Share by Country, 2024 VS 2031
6.7 Middle East & Africa
6.7.1 Middle East & Africa Nonalcoholic Steatohepatitis Treatment Sales Value (2020-2031)
6.7.2 Middle East & Africa Nonalcoholic Steatohepatitis Treatment Sales Value Share by Country, 2024 VS 2031
7 Nonalcoholic Steatohepatitis Treatment Country-level Value Analysis
7.1 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Country: 2020 VS 2024 VS 2031
7.2 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Country (2020-2031)
7.2.1 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Country (2020-2025)
7.2.2 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Country (2026-2031)
7.3 USA
7.3.1 USA Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2020-2031)
7.3.2 USA Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2024 VS 2031
7.3.3 USA Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2024 VS 2031
7.4 Canada
7.4.1 Canada Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2020-2031)
7.4.2 Canada Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2024 VS 2031
7.4.3 Canada Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2024 VS 2031
7.5 Mexico
7.5.1 Mexico Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2020-2031)
7.5.2 Mexico Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2024 VS 2031
7.5.3 Mexico Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2024 VS 2031
7.6 Germany
7.6.1 Germany Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2020-2031)
7.6.2 Germany Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2024 VS 2031
7.6.3 Germany Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2024 VS 2031
7.7 France
7.7.1 France Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2020-2031)
7.7.2 France Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2024 VS 2031
7.7.3 France Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2024 VS 2031
7.8 U.K.
7.8.1 U.K. Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2020-2031)
7.8.2 U.K. Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2024 VS 2031
7.8.3 U.K. Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2024 VS 2031
7.9 Italy
7.9.1 Italy Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2020-2031)
7.9.2 Italy Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2024 VS 2031
7.9.3 Italy Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2024 VS 2031
7.10 Spain
7.10.1 Spain Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2020-2031)
7.10.2 Spain Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2024 VS 2031
7.10.3 Spain Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2024 VS 2031
7.11 Russia
7.11.1 Russia Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2020-2031)
7.11.2 Russia Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2024 VS 2031
7.11.3 Russia Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2024 VS 2031
7.12 Netherlands
7.12.1 Netherlands Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2020-2031)
7.12.2 Netherlands Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2024 VS 2031
7.12.3 Netherlands Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2024 VS 2031
7.13 Nordic Countries
7.13.1 Nordic Countries Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2020-2031)
7.13.2 Nordic Countries Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2024 VS 2031
7.13.3 Nordic Countries Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2024 VS 2031
7.14 China
7.14.1 China Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2020-2031)
7.14.2 China Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2024 VS 2031
7.14.3 China Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2024 VS 2031
7.15 Japan
7.15.1 Japan Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2020-2031)
7.15.2 Japan Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2024 VS 2031
7.15.3 Japan Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2024 VS 2031
7.16 South Korea
7.16.1 South Korea Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2020-2031)
7.16.2 South Korea Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2024 VS 2031
7.16.3 South Korea Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2024 VS 2031
7.17 India
7.17.1 India Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2020-2031)
7.17.2 India Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2024 VS 2031
7.17.3 India Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2024 VS 2031
7.18 Australia
7.18.1 Australia Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2020-2031)
7.18.2 Australia Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2024 VS 2031
7.18.3 Australia Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2024 VS 2031
7.19 Southeast Asia
7.19.1 Southeast Asia Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2020-2031)
7.19.2 Southeast Asia Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2024 VS 2031
7.19.3 Southeast Asia Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2024 VS 2031
7.20 Brazil
7.20.1 Brazil Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2020-2031)
7.20.2 Brazil Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2024 VS 2031
7.20.3 Brazil Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2024 VS 2031
7.21 Argentina
7.21.1 Argentina Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2020-2031)
7.21.2 Argentina Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2024 VS 2031
7.21.3 Argentina Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2024 VS 2031
7.22 Chile
7.22.1 Chile Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2020-2031)
7.22.2 Chile Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2024 VS 2031
7.22.3 Chile Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2024 VS 2031
7.23 Colombia
7.23.1 Colombia Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2020-2031)
7.23.2 Colombia Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2024 VS 2031
7.23.3 Colombia Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2024 VS 2031
7.24 Peru
7.24.1 Peru Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2020-2031)
7.24.2 Peru Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2024 VS 2031
7.24.3 Peru Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2024 VS 2031
7.25 Saudi Arabia
7.25.1 Saudi Arabia Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2020-2031)
7.25.2 Saudi Arabia Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2024 VS 2031
7.25.3 Saudi Arabia Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2024 VS 2031
7.26 Israel
7.26.1 Israel Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2020-2031)
7.26.2 Israel Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2024 VS 2031
7.26.3 Israel Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2024 VS 2031
7.27 UAE
7.27.1 UAE Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2020-2031)
7.27.2 UAE Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2024 VS 2031
7.27.3 UAE Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2024 VS 2031
7.28 Turkey
7.28.1 Turkey Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2020-2031)
7.28.2 Turkey Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2024 VS 2031
7.28.3 Turkey Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2024 VS 2031
7.29 Iran
7.29.1 Iran Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2020-2031)
7.29.2 Iran Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2024 VS 2031
7.29.3 Iran Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2024 VS 2031
7.30 Egypt
7.30.1 Egypt Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2020-2031)
7.30.2 Egypt Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2024 VS 2031
7.30.3 Egypt Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Arena Pharmaceuticals
8.1.1 Arena Pharmaceuticals Comapny Information
8.1.2 Arena Pharmaceuticals Business Overview
8.1.3 Arena Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2020-2025)
8.1.4 Arena Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Product Portfolio
8.1.5 Arena Pharmaceuticals Recent Developments
8.2 Arisaph Pharmaceuticals
8.2.1 Arisaph Pharmaceuticals Comapny Information
8.2.2 Arisaph Pharmaceuticals Business Overview
8.2.3 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2020-2025)
8.2.4 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Product Portfolio
8.2.5 Arisaph Pharmaceuticals Recent Developments
8.3 Cempra Pharmaceuticals
8.3.1 Cempra Pharmaceuticals Comapny Information
8.3.2 Cempra Pharmaceuticals Business Overview
8.3.3 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2020-2025)
8.3.4 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Product Portfolio
8.3.5 Cempra Pharmaceuticals Recent Developments
8.4 Galectin Therapeutics
8.4.1 Galectin Therapeutics Comapny Information
8.4.2 Galectin Therapeutics Business Overview
8.4.3 Galectin Therapeutics Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2020-2025)
8.4.4 Galectin Therapeutics Nonalcoholic Steatohepatitis Treatment Product Portfolio
8.4.5 Galectin Therapeutics Recent Developments
8.5 Galmed Pharmaceuticals
8.5.1 Galmed Pharmaceuticals Comapny Information
8.5.2 Galmed Pharmaceuticals Business Overview
8.5.3 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2020-2025)
8.5.4 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Product Portfolio
8.5.5 Galmed Pharmaceuticals Recent Developments
8.6 Genfit
8.6.1 Genfit Comapny Information
8.6.2 Genfit Business Overview
8.6.3 Genfit Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2020-2025)
8.6.4 Genfit Nonalcoholic Steatohepatitis Treatment Product Portfolio
8.6.5 Genfit Recent Developments
8.7 Gilead
8.7.1 Gilead Comapny Information
8.7.2 Gilead Business Overview
8.7.3 Gilead Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2020-2025)
8.7.4 Gilead Nonalcoholic Steatohepatitis Treatment Product Portfolio
8.7.5 Gilead Recent Developments
8.8 Novo Nordisk
8.8.1 Novo Nordisk Comapny Information
8.8.2 Novo Nordisk Business Overview
8.8.3 Novo Nordisk Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2020-2025)
8.8.4 Novo Nordisk Nonalcoholic Steatohepatitis Treatment Product Portfolio
8.8.5 Novo Nordisk Recent Developments
8.9 Vivus
8.9.1 Vivus Comapny Information
8.9.2 Vivus Business Overview
8.9.3 Vivus Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2020-2025)
8.9.4 Vivus Nonalcoholic Steatohepatitis Treatment Product Portfolio
8.9.5 Vivus Recent Developments
8.10 AstraZeneca
8.10.1 AstraZeneca Comapny Information
8.10.2 AstraZeneca Business Overview
8.10.3 AstraZeneca Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2020-2025)
8.10.4 AstraZeneca Nonalcoholic Steatohepatitis Treatment Product Portfolio
8.10.5 AstraZeneca Recent Developments
8.11 GSK
8.11.1 GSK Comapny Information
8.11.2 GSK Business Overview
8.11.3 GSK Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2020-2025)
8.11.4 GSK Nonalcoholic Steatohepatitis Treatment Product Portfolio
8.11.5 GSK Recent Developments
8.12 Roche
8.12.1 Roche Comapny Information
8.12.2 Roche Business Overview
8.12.3 Roche Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2020-2025)
8.12.4 Roche Nonalcoholic Steatohepatitis Treatment Product Portfolio
8.12.5 Roche Recent Developments
9 Concluding Insights
10 Appendix
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.